Financial Performance - For the year ended December 31, 2024, the company generated $180.4 million in revenue, a decline of approximately 7.9% compared to $195.9 million in 2023[21]. - For the year ended December 31, 2024, the company generated approximately $180 million in revenue, reflecting a 7.9% decline compared to approximately $196 million in 2023[36]. - The company has experienced rapid growth but has limited operating experience at its current scale, which may strain resources and affect financial performance[94]. - The company may face challenges in generating sufficient cash flow from operations to meet debt service obligations, which could adversely affect its financial condition[165]. - Macroeconomic trends, including rising inflation and interest rates, may adversely impact the company's financial condition and results of operations[91]. Operational Highlights - The company performed 14,036 body contouring procedures in 2024, showcasing its operational scale[18]. - The company operates 32 centers across 20 U.S. states, Canada, and the United Kingdom as of March 14, 2025[18]. - As of March 14, 2025, the company operates 32 centers across 20 U.S. states, Canada, and the United Kingdom, with an average revenue per case of $12,849 in 2024[34]. - The company plans to expand its footprint by opening new centers in North America, with over 200 potential locations identified[43]. - The company plans to open five new centers in 2024, focusing on densely populated and affluent metropolitan and suburban regions[104]. Marketing and Customer Acquisition - The company focuses on optimizing marketing investments and improving sales strategies to stabilize revenue growth[22]. - Total advertising costs for the year ended December 31, 2024, were $33.4 million, with approximately 90% allocated to digital advertising[53]. - Customer acquisition costs were approximately $3,130 per customer in 2024[54]. - The company has a catalog of over 250,000 "before and after" photos to showcase treatment outcomes, supporting its marketing efforts[42]. - In 2024, approximately 52% of cases involved patients securing third-party financing, enhancing affordability and driving sales growth[56]. Competitive Landscape - The company competes in the body contouring market against traditional liposuction providers, which typically require longer recovery times[60]. - The body contouring market is highly competitive, with numerous competitors offering alternative solutions that could limit demand for the AirSculpt procedure[111]. - The competitive landscape includes non-surgical fat reduction methods, which are gaining traction in the market[60]. - The company faces risks related to competition, including the potential for competitors to develop safer or more effective solutions[85]. Regulatory and Compliance Issues - Regulatory scrutiny in states like California, Massachusetts, and New York is increasing, potentially impacting the company's structure and operations[70]. - The company emphasizes the importance of maintaining necessary licenses and compliance with healthcare regulations to ensure operational profitability[73]. - The company is subject to various federal and state laws related to healthcare fraud and abuse, and violations could result in significant penalties[88]. - Changes in laws and regulations related to telehealth could adversely affect the company's ability to provide virtual consultations, potentially increasing operational costs[128][129]. Management and Strategy - The company hired a new CEO, Yogi Jashnani, in January 2025, to drive revenue growth through strategic initiatives[23]. - The management team includes experienced leaders with backgrounds in healthcare and private equity, supporting the company's growth strategy[37]. - The company is implementing cost-saving initiatives and revenue growth strategies in response to a decline in revenue during the 2024 fiscal year[90]. - The long-term growth strategy includes opportunistic expansion by opening new centers, although many centers are relatively new and may not generate comparable revenue[96]. Risks and Challenges - The company faces challenges in maintaining profitability levels for newly opened centers, which may not achieve expected sales or profitability[106]. - The ongoing military conflict between Russia and Ukraine has negatively impacted the global economy, potentially affecting the company's financial condition and operations[118]. - Economic downturns could adversely impact consumer spending on discretionary services, including cosmetic procedures, affecting the company's financial condition[146]. - The company may face increased scrutiny and regulation regarding data privacy and security, which could limit its ability to use social media for brand awareness[126]. Intellectual Property and Technology - The patent portfolio includes two issued U.S. utility patents and one pending U.S. utility patent application, with expectations for patents to expire in 2033 or later[57]. - The patent prosecution process is complex and costly, and the company may not be able to maintain or enforce all necessary patents, affecting its ability to commercialize new technologies[200]. - Changes in patent laws or their interpretation could diminish the company's ability to protect its inventions and may lead to increased costs[203]. - The company may become involved in costly intellectual property litigation, which could interfere with its ability to market and perform its services[209]. Financial Obligations and Debt - As of December 31, 2024, total outstanding indebtedness under the senior credit facility was approximately $75.8 million, consisting of $70.8 million in term loans and $5.0 million drawn on the revolving credit facility[155]. - The company is required to maintain a minimum liquidity of $3 million as of March 31, 2025, increasing to $7.5 million thereafter[158]. - The Consolidated Fixed Charge Coverage Ratio must be no less than 0.50x and 1.10x for the fiscal quarters ending March 31, 2025, and June 30, 2025, respectively[158]. - The company has pledged substantially all of its assets as security under the Term Loan and Revolving Credit Facility, which could be at risk if unable to meet debt obligations[162]. Human Resources - As of December 31, 2024, the company employed approximately 389 full-time employees and 33 part-time employees, along with contracts with about 97 surgeons[77]. - The ability to recruit and train qualified surgeons is essential for the successful operation of new centers[108]. - The company faces intense competition for surgeons from other cosmetic treatment centers, which could hinder its ability to implement business strategies successfully[131][132]. Cybersecurity and Data Management - Cybersecurity threats pose significant risks to the company's operations, potentially leading to data breaches and operational disruptions[186]. - The company is highly dependent on information technology networks and systems to securely process sensitive data, including individually identifiable health information (IIHI) and personally identifiable information (PII)[192]. - Security breaches could lead to significant costs for investigation, containment, remediation, and compliance with breach notification laws, potentially harming the company's reputation and financial condition[196]. - The company has implemented administrative, physical, and technological safeguards to address cybersecurity risks, but these measures may not adequately protect against all potential threats[194].

AirSculpt Technologies, Inc. (AIRS) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of $0.02. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -500%. A quarter ago, it was expected that this company would post earnings of $0.04 per share when it actually produced a loss of $0.02, delivering a surprise of -150%.Over the last four quarters, the company has n ...

Revenue Guidance - AirSculpt Technologies, Inc. updated its full year 2024 revenue guidance, indicating a significant increase compared to previous estimates[5] Adjusted EBITDA Guidance - The company also provided Adjusted EBITDA guidance for 2024, reflecting improved operational efficiency and profitability[5] Transparency Commitment - The press release detailing these updates was issued on January 13, 2025, highlighting the company's commitment to transparency[5]

Core Insights - AirSculpt Technologies, Inc. reported a challenging year in 2024, with a focus on stabilizing same-center sales performance and implementing strategic changes to enhance shareholder value [2][4]. Financial Performance - For Q4 2024, case volume decreased by 16.7% to 3,064 from 3,680 in Q4 2023, while revenue fell by 17.7% to $39.2 million from $47.6 million [6][17]. - The net loss for Q4 2024 was $5.0 million, compared to a net loss of $4.6 million in Q4 2023, and adjusted EBITDA dropped to $1.9 million from $10.1 million [6][17]. - For the full year 2024, case volume declined by 6.0% to 14,036 from 14,932 in 2023, with revenue decreasing by 7.9% to $180.4 million from $195.9 million [6][17]. - The net loss for the full year 2024 was $8.3 million, compared to a net loss of $4.5 million in 2023, and adjusted EBITDA was $20.7 million, down from $43.2 million [6][17]. Liquidity and Cash Flow - As of December 31, 2024, the company had $8.2 million in cash and cash equivalents, with no availability on its revolving credit facility [4][19]. - Operating cash flow for the year was $11.4 million, a significant decrease from $24.0 million in 2023 [4][19]. Strategic Initiatives - The CEO emphasized the importance of utilizing data to optimize marketing investments, improving the go-to-market strategy, and expanding financing options for consumers [2][4]. - A cost reduction program is expected to yield approximately $3 million in annualized savings, and the company has paused new procedure room openings to focus on existing operations [2][4]. Operational Metrics - The company operated 32 centers as of December 31, 2024, an increase from 27 centers in the previous year [19]. - Revenue per case for Q4 2024 was $12,787, slightly down from $12,937 in Q4 2023 [19][21].

Core Viewpoint - Three stocks have been added to the Zacks Rank 5 (Strong Sell) List, indicating a negative outlook for these companies based on recent earnings estimate revisions. Group 1: Company Specifics - ATS Corporation (ATS) is an automation solutions provider, with the Zacks Consensus Estimate for its current year earnings revised downward by 8.1% over the last 60 days [1] - AirSculpt Technologies, Inc. (AIRS) is a body contouring services provider, with the Zacks Consensus Estimate for its current year earnings revised downward by 14.3% over the last 60 days [1] - Dine Brands Global, Inc. (DIN) is a restaurant chain operator, with the Zacks Consensus Estimate for its current year earnings revised downward by 13.4% over the last 60 days [2]

Company Overview - AirSculpt Technologies, Inc. is a leader in the premium body contouring industry, offering next-generation treatments designed for comfort and precision [3] - The company operates 31 centers in North America and one location in the United Kingdom, providing minimally invasive procedures that remove fat and tighten skin [3] Financial Announcement - AirSculpt will report its fourth quarter 2024 financial results before the market opens on March 14, 2025, followed by a conference call at 8:30 a.m. Eastern Time [1] - The conference call can be accessed via a toll-free number or through a live webcast on the company's investor relations website [2]

Core Viewpoint - AirSculpt Technologies, Inc. has updated its fiscal year 2024 guidance, indicating a shift in expected financial performance as the company aims to stabilize revenue and return to growth under new CEO Yogi Jashnani's leadership [1][2][3]. Financial Performance - The company expects revenues of approximately $180 million, a decrease from the previous guidance of $183 million to $189 million [6]. - Adjusted EBITDA is projected to be around $20.5 million, down from the earlier guidance of $23 million to $28 million [6]. Leadership and Strategy - Yogi Jashnani has officially started as CEO and emphasizes leveraging the company's proprietary technology and asset-light business model to drive long-term profitable growth [2]. - The CEO plans to implement business process changes and enhance technology and consumer insights to inform marketing, real estate, and sales decisions [2]. Business Model and Operations - AirSculpt operates 32 centers globally, with a strong foundation based on over 70,000 successful procedures [2]. - The company offers a next-generation body contouring treatment that is minimally invasive, designed for quick healing and precise results [8]. Upcoming Events - AirSculpt will participate in the ICR Conference 2025, where the CEO and CFO will present insights into the company's business model and future strategy [7].

Company Overview - AirSculpt Technologies, Inc. is an industry leader in premium body contouring procedures, offering next-generation treatments designed for comfort and precision [3] - The company operates 31 centers in North America and one location in the United Kingdom, providing minimally invasive procedures that remove fat and tighten skin [3] Upcoming Events - AirSculpt will participate in investor meetings and host a presentation at the ICR Conference 2025 from January 13 to January 14, 2025, in Orlando, Florida [1] - The presentation will be led by CEO Yogi Jashnani and CFO Dennis Dean on January 14, 2025, at 10:00 a.m. Eastern Standard Time, and will be available via live webcast [2] Investor Relations - An archive of the webcast presentation will be accessible for 90 days following the event [2] - The company utilizes its website as a distribution channel for material information, which is routinely updated and readily accessible [4]

Core Viewpoint - AirSculpt Technologies, Inc. has appointed Yogi Jashnani as the new CEO, effective January 7, 2025, succeeding Dennis Dean, who will remain as CFO [1][3]. Company Leadership - Yogi Jashnani brings over two decades of experience in transforming public and private companies across various industries, including aesthetics and finance [2]. - Dr. Aaron Rollins, Executive Chairman, expressed confidence in Jashnani's ability to enhance company value and capitalize on AirSculpt's strengths, including proprietary technology and a large addressable market [3]. Strategic Focus - Jashnani aims to stabilize and accelerate same-center sales growth, enhance operational efficiencies, and unlock the full potential of the AirSculpt method [3]. - The company has a strong foundation with innovative technology and significant market opportunities, which Jashnani plans to leverage for growth [3]. Previous Experience - Prior to joining AirSculpt, Jashnani served as Chief Revenue Officer at Sky Zone and held executive roles at Ideal Image, Advance Auto Parts, and Capital One Financial Services [2][4]. - At Ideal Image, he drove revenue growth through the introduction of new services and a loyalty membership program [2]. Company Overview - AirSculpt offers a next-generation body contouring treatment that is minimally invasive, designed for comfort and precision, and available at 31 centers in North America and one in the UK [5].

Company Overview - AirSculpt® Technologies, Inc. is a leader in premium body contouring procedures and has opened its 32nd clinic in White Plains, New York [1][4] - The company has performed over 60,000 AirSculpt® cases since 2012 across the U.S., Canada, and the United Kingdom [4] New Clinic Details - The new White Plains center features three operating rooms, allowing for simultaneous procedures [2] - The clinic will offer the AirSculpt®+ skin tightening procedure, which enhances the results of the fat removal process [2][3] Strategic Expansion - The opening of the White Plains clinic is part of a strategic expansion into New York, driven by increasing market demand [3] - The AirSculpt®+ procedure combines fat removal with skin tightening using Renuvion®, which utilizes helium gas and radiofrequency energy [3][5]